Feed LNTH
LN

Lantheus LNTH NASDAQ · Healthcare · United States

$102.10 +0.00% +$0.00

Summary

77 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 104% a year over the last 3 years.
  • Out of every 100 USD of revenue, 17 USD is left as net profit.
  • It holds more cash than debt: $683.6M against $54.0M.
  • It bought back its own shares for $300.0M in the last fiscal year, 4.5% of its market value.

What to watch

  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $102.1

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 24.7 46% lower
5-year average P/E 45.4
P/E today 24.7
Drug Manufacturers - Specialty & Generic industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 24.7 USD for 1 USD of yearly profit. Over the last five years it was 45.4 USD on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 35% a year over 5 years. Over the last 3 years it grew by 18% a year. Earnings per share grew by 104% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD

Out of every 100 USD of revenue, 17 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $102.65 is 0.5% above today's price. 53% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Product brings in 33% of revenue. PYLARIFY grew fastest, by 118% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy